# Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery

> **NCT03647774** · PHASE4 · COMPLETED · sponsor: **Lars Tanum** · enrollment: 317 (actual)

## Conditions studied

- Opioid-use Disorder

## Interventions

- **DRUG:** Extended release naltrexone

## Key facts

- **NCT ID:** NCT03647774
- **Lead sponsor:** Lars Tanum
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2022-12-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647774, "Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03647774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*